Urine Alkalinization for UTI in Women: RCT
ConditionUTI - Urinary Tract Infection
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorAssiut University
About this trial
The goal of this clinical trial is to evaluate whether urinary alkalinization using potassium citrate can relieve symptoms and improve urine culture results in women aged 18 to 50 years with uncomplicated urinary tract infections (UTIs). The main questions it aims to answer are:
Does urinary alkalinization reduce UTI symptom scores by Day 7?
Does it lead to better urine culture results compared to antibiotic?
Researchers will compare urinary alkalinization with potassium citrate to antibiotic to see if it provides more symptom relief and better microbiological outcomes.
Participants will:
Take either potassium citrate or antibiotic
Be assessed for symptoms and adverse events on Day 7
Provide a urine sample for culture before and after treatment
Report any return visits due to worsening symptoms or medication side effects
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Women aged ≥ 18 and ≤ 50.
Symptoms of uncomplicated UTI or cystitis; including urinary frequency, urgency and dysuria.
Positive urine culture of mid-urine urine.
Disqualifiers
Post menopausal women.
Pregnancy.
Complicated UTIs, such as those requiring hospital admission, infections associated with fevers, those with urinary tract abnormalities, urinary tract calculi or urinary tract obstruction.
History of recurrent UTI.
Trial design
Design model
Parallel
Treatments tested in this trial
potassium citrate
DrugPotassium citrate is a medication used to alkalinize the urine, providing symptomatic relief of dysuria in patients with urinary tract infections (UTIs). In this study, participants in Arm 1 will receive potassium citrate for a period of 7 days. The treatment is aimed at reducing discomfort related to UTIs, such as burning sensations during urination and suprapubic pain. In addition to symptomatic relief, the intervention may also enhance bacterial phagocytosis and bacterial killing in the urine. Participants will be monitored for any side effects or adverse events during the treatment period.
Nitrofurantoin
DrugNitrofurantoin is an antibiotic commonly used to treat uncomplicated urinary tract infections (UTIs). In this arm, participants will receive Nitrofurantoin for 7 days to treat their UTI. The primary objective is to evaluate its effectiveness in reducing UTI symptoms, such as dysuria, urgency, frequency, and suprapubic discomfort. This intervention will be compared with the urinary alkalinization therapy used in Arm 1. Researchers will also monitor changes in urine culture and any adverse events related to the antibiotic treatment.
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Potassium Citrate Treatment for UTI Symptom ReliefActive comparator 1 intervention
Group B: Nitrofurantoin Antibiotic Treatment for UTIActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Symptom Relief (Dysuria, Urgency, and Frequency) in UTI Patients Treated with Potassium Citrate vs. Nitrofurantoin
The primary outcome of this study is the reduction in urinary tract infection (UTI) symptoms, specifically dysuria (painful urination), urgency, and frequency, after 7 days of treatment with either Potassium Citrate or Nitrofurantoin. The severity of these symptoms will be measured using a standardized symptom questionnaire, where participants will rate the intensity of their symptoms at baseline (pre-treatment), day 3, and day 7. A reduction of ≥50% in symptom severity will be considered clinically significant. The results will be compared between the Potassium Citrate and Nitrofurantoin groups to determine which treatment is more effective in relieving UTI symptoms.
Time frame
7 days (Participants will be assessed at baseline, day 3, and day 7).Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: